Anatomic Stage IIIA Breast Cancer AJCC v8 Not Yet Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0109626 (Anatomic Stage IIIA Breast Cancer AJCC v8)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06324240Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerTreatment